NCT01087970

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 69 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.

Conditions

• Head and Neck Neoplasms

Interventions

Type	Name	Description
DRUG	Pemetrexed	Administered intravenously, for maximum of 6 cycles.
DRUG	Cetuximab	Administered intravenously in combination therapy, for a maximum of 6 cycles. After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.
DRUG	Carboplatin	Administered intravenously, for a maximum of 6 cycles
DRUG	Cisplatin	Administered intravenously, for a maximum of 6 cycles

Timeline

• Start date: 2010-08-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2010-03-16
• Last updated: 2014-05-19
• Results posted: 2014-05-19

Locations

21 sites across 1 country: United States